comprehensive -WSS

comprehensive

author：fashion 2025-09-05 11:31:06 - browse：98

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Fentanyl is making it harder to start addiction treatment

hotspot

WSS

Apellis safety probe of eye disease drug centers on injection needle

Apellis safety probe of eye disease drug centers on injection needle

Cue Health, Covid

Fentanyl is making it harder to start addiction treatment

H5N1 bird flu outbreak: Second human case reported, in Michigan

What AAP's gender

focus

comprehensive

focus

Apple is now the first public company to be valued at $3 trillion

CDC advisory panel says seniors 'may' get RSV vaccine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA poised to publish guidelines for clinical trial diversity

In Memoriam: Notable people who died in 2023

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

How to save PrEP access — and even expand it

FDA panel gives mixed vote on blood pressure devices

focus

Making the case for fair compensation in clinical trials

Listen: More tumult at BIO & coercive care for sickle cell patients

For longer

Medicare explains how it will choose drugs for negotiation

Digital health: a case of mistaken identity

Medicare explains how it will choose drugs for negotiation

Wikipedia

hotspot

hotspot

hotspot